|
|
| |
| Articles
by
Mojtaba Azimian |
Total Records (
2 ) for
Mojtaba Azimian |
|
 |
| |
|
| |
Mojtaba Azimian
,
A. Shahvarughi Farahani
,
Asghar Dadkhah
,
M. Fallahpour
and
M. Karimlu
|
| |
As fatigue is highly prevalent and has a negative impact on quality of life and performance in a variety of disorders and Fatigue Severity Scale (FSS) is one of the most commonly used self-reported questionnaires to measure fatigue. The aim of this study was to evaluate different aspects of Validity and Reliability of the Persian-version of Fatigue Severity Scale (FSS-P) among people with multiple sclerosis. A sample of 50 people with Relapsing-Remitting type of multiple sclerosis and 30 Healthy Adult were included in this study. The participants were recruited from M.S clinic in Tehran between 2001-2007. The Fatigue Severity Scale (FSS) includes nine items developed to measure disabling fatigue and a Visual Analog Scale (VAS) to measure overall fatigue. A sample of asked to complete FSS and Short-form 36 Health Survey (SF-36) questionnaires. Test-retest reliability and Internal Consistency were assessed, using Intraclass Correlation Coefficient (ICC) and Cronbach's alpha, respectively. Dimensionality was assessed, using item-scale correlation after correction for overlap and convergent validity, using a priori hypothesized correlations with the SF-36. All the participants found the FSS-P to be clear and unambiguous in pilot testing. The ICC was reported 0/93 for the total score and 0/88 for VAS, The Cronbach's alpha was reported 0/96. The total score and the VAS were significantly correlated with the SF-36 vitality subscale (r = -0/69 and r = -0/73, respectively). Correlations with other SF-36 subscales were moderate (r = -0/43 to r = -0/65, all p<0.001). The results of the study revealed that the FSS-P is an appropriate instrument psychometrically to assess the people with multiple sclerosis. |
|
| |
|
| |
Mahmoud Gh. Mirzaei
,
Mojtaba Azimian
,
Mahmoud Rafieian-Kopaei
and
Bijan Khorasany
|
| |
Lamotrigine is effective in migraine with aura (classic migraine). However, its usefulness in migraine without aura (common migraine) is not clearly established. The purpose was to investigate the activity of lamotrigine on migraine with aura in comparison with any activity on migraine without aura in younger patients. In the study, 155 patients aged 4-14 years, suffering migraine headaches were diagnosed using International Headache Society (IHS) criteria. About 24 (15.5%) patients suffered classic migraine and 131 (84.5%) had common migraine. Each patient was prescribed lamotrigine (0.5 up to 3 mg/kg/day) for 6 months and evaluated monthly. Migraine frequency and intensity were recorded for 2 months before drug usage and 6 months during lamotrigine administration (acetaminophen was prescribed if needed). Lamotrigine induced a 45.2 and 17.1% reduction in the frequency of migraine attacks with and without aura, respectively. It also produced a 41.3 and 28.9% reduction in intensity of migraine with and without aura, respectively. About 14 patients in the classic migraine group and 23 patients in common migraine group were markedly improved (p<0.001). The results demonstrate that in younger patients, lamotrigine reduces both frequency and intensity of migraine in the presence and absence of aura. |
|
|
|
|
| |
|
